Abstract
Melanoma is a malignant neoplasm that originates from melanocytes and although it corresponds to only 3% of skin cancers, it is responsible for 80% of deaths. This is because metastatic Melanoma is refractory to conventional and targeted therapies and because it quickly acquires resistance to specific inhibitors of mutated proteins in the MAPK pathway, such as BRAF. In silico screening st…